N-terminal specificity of PEGylation of human bone morphogenetic protein-2 at acidic pH

International Journal of Pharmaceutics

Volumn 413, Issue 1-2, 2011, Pages 140-146

  Hu, Junli ^a,b   Sebald, Walter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b NONE   (United States)

Author keywords

Bone morphogenetic protein; PEGylation; Specificity

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; MACROGOL;

AMINO TERMINAL SEQUENCE; ARTICLE; DRUG ACTIVITY; DRUG SPECIFICITY; HUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; RECEPTOR BINDING;

EID: 79957988813     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.04.043     Document Type: Article

References (30)

1. H. Bentz, J.A. Schroeder, and T.D. Estridge Improved local delivery of TGF-β2 by binding to injectable fibrillar collagen via difunctional polyethylene glycol J. Biomed. Mater. Res. 39 1998 539 548 (Pubitemid 28079715)
2. K. Brebda, R. Mann, H. Schmedlen, and J.L. West Tethered-TGF-β increases extracellular matrix production of vascular smooth muscle cells Biomaterials 22 2001 439 444 (Pubitemid 32007848)
3. P. Caliceti, and M.F. Veronese Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates Adv. Drug Deliver. Rev. 55 2003 1261 1277 (Pubitemid 37464561)
4. J. Groppe, K. Rumpel, A.N. Economides, N. Stahl, W. Sebald, and M. Affolter Biochemical and biophysical characterization of refolded Drosophila DPP, a homolog of bone morphogenetic protein 2 and 4 J. Biol. Chem. 273 1998 29052 29065 (Pubitemid 28507601)
5. B.L. Hogan Bone morphogenetic proteins in development Curr. Opin. Genet. Dev. 6 1996 432 438 (Pubitemid 26280795)
6. J.L. Hu, V. Duppatla, S. Harsh, W. Schmitz, and W. Sebald Site-specific PEGylation of bone morphology protein-2 cysteine analogues Bioconjugate Chem. 21 2010 1762 1772
7. Kinstler, O., Gabriel, N., Farrar, C., DePrince, R., 1997. N-terminally chemically modified protein compositions and methods. US Patent 005,985,265.
8. O. Kinstler, G. Molineux, M. Treuheit, D. Ladd, and C. Gegg Mono-N-terminal poly(ethylene glycol)-protein conjugates Adv. Drug Deliver. Rev. 54 2002 477 485 (Pubitemid 34615544)
9. T. Kirsch, J. Nickel, and W. Sebald BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II EMBO J. 19 2000 3314 3324 (Pubitemid 30428209)
10. F.N. Kwong, and M.B. Harris Recent developments in the biology of fracture repair J. Am. Acad. Orthop. Surg. 16 2008 619 625
11. U.K. Laemmli Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 227 1970 680 685
12. H. Lee, H. Jang, S.H. Ryu, and T.G. Park N-terminal site-specific mono-PEGylation of epidermal growth factor Pharm. Res. 20 2003 818 824
13. S.H. Lee, S. Lee, D.H. Na, S.Y. Chae, Y. Byun, and K.C. Lee Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1 Bioconjugate Chem. 16 2005 377 382 (Pubitemid 40388214)
14. H.W. Liu, C.H. Chen, C.L. Tsai, I.H. Lin, and G.H. Hsiue Heterobifunctional poly(ethylene glycol)-tethered bone morphogenetic protein-2-stimulated bone marrow mesenchymal stromal cell differentiation and osteogenesis Tissue Eng. 13 2007 1113 1124
15. P.R.E. Mittl, J.P. Priestle, D.A. Cox, G. Mcmaster, N. Cerletti, and M.G. Grütter The crystal structure of TGF-β3 and comparison to TGF-β2: implications for receptor binding Protein Sci. 5 1996 1261 1271 (Pubitemid 26239434)
16. Y. Nie, X. Zhang, X. Wang, and J. Chen Preparation and stability of N-terminal mono-PEGylated recombinant human endostatin Bioconjugate Chem. 17 2006 995 999 (Pubitemid 44162618)
17. J. Pellaud, U. Schote, T. Arvinte, and J. Seelig Conformation and self-association of human recombinant transforming growth factor-β3 in aqueous solutions J. Biol. Chem. 274 1999 7699 7704
18. A.H. Reddi Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian morphogens Cytokine Growth Factor Rev. 8 1997 11 20 (Pubitemid 27214686)
19. A.H. Reddi Role of morphogenetic proteins in skeletal tissue engineering and regeneration Nat. Biotechnol. 16 1998 247 252
20. Y. Robinson, C.E. Heyde, S.K. Tschoke, M.A. Mont, T.M. Seyler, and S.D. Ulrich Evidence supporting the use of bone morphogenetic proteins for spinal fusion surgery Expert Rev. Med. Dev. 5 2008 75 84
21. S.M. Rosendahl, H.D. Doherty, J.D. Smith, J.S. Carlson, A.E. Chlipala, and G.N. Cox A long-acting, highly potent interferon α-2 conjugate created using site-specific PEGylation Bioconjugate Chem. 16 2009 200 207 (Pubitemid 40129694)
22. R. Ruppert, E. Hoffmann, and W. Sebald Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity Eur. J. Biochem. 237 1996 295 302 (Pubitemid 26110301)
23. C. Scheufler, W. Sebald, and M. Huelsmeyer Crystal structure of human bone morphogenetic protein-2 at 2.7 resolution J. Mol. Biol. 287 1999 103 115 (Pubitemid 29134800)
24. W. Sebald, J. Nickel, J. Zhang, and T.D. Müller Molecular recognition in bone morphogenetic protein (BMP)/receptor interaction Biol. Chem. 385 2004 697 710 (Pubitemid 39255628)
25. H. Seeherman, and J.M. Wozney Delivery of bone morphogenetic proteins for orthopedic tissue regeneration Cytokine Growth Factor Rev. 16 2005 329 345 (Pubitemid 40910322)
26. M.F. Veronese, A. Mero, F. Caboi, M. Sergi, C. Marongiu, and G. Pasut Site-specific PEGylation of G-CSF by reversible denaturation Bioconjugate Chem. 18 2007 1824 1830 (Pubitemid 350219980)
27. M.F. Veronese, and G. Pasut PEGylation, a successful approach to drug delivery Drug Discov. Today 10 2005 1451 1458 (Pubitemid 41483874)
28. S.S. Wong Chemistry of Protein Conjugation and Cross-linking 1991 CRC Press Boca Raton, FL
29. D.C. Wylie, M. Voloch, S. Lee, Y.H. Liu, S.C. Carlson, C. Cutler, and B. Pramanik Carboxyalkylated histidine is a pH-dependent product of PEGylation with SC-PEG Pharm. Res. 18 2001 1354 1360 (Pubitemid 32846332)
30. H. Zappe, M.E. Snell, and M.J. Bossard PEGylation of cyanovirin-N, an entry inhibitor of HIV Adv. Drug Deliver. Rev. 60 2008 79 87 (Pubitemid 350181168)